"conventional surgery Prostate Cancer" Channels 
BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.
Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html
Interested? Contact priority@bioportfolio.com
Showing "conventional surgery Prostate Cancer" Channels 1–25 of 174
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers.The cancer cells may metastasize (spread) from the...
Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or African ethnicity. Treatment options depend on whe...
Prostate Cancer Cellular Vaccine rDNA
The most common system to evaluate and describe prostate cancer currently in use is the Gleason grading system. After a biopsy, the pathologist assigns a primary grade from 1 to 5, with 5 being the most aggressive, to the pattern of cancer cells occupyin...
What is new in prostate cancer research and development?
Key research areas in relation to Prostate Cancer are discussed below. Brief descriptions are supported by hyperlinks to the most relevant research papers and current affairs news reports and blog postings - follow these links for more detailed inf...
Breast cancer in the UK is diagnosed in nearly 46,000 people each year, with just over 12,000 dying from breast cancer each year in he UK. There are several risk factors for developing breast cancer including age and a family history of the d...
Prostate specific membrane antigen PSMA
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy. PSMA represents an attractive antigen for...
Ovarian cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian cancer are those who have had few children (or had children at an older age), carriers o...
On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prostate cancer (CPRC) following failed Taxotere (docetaxel)...
Endocrine Disrupting Chemicals (EDCs)
Endocrine disrupting chemicals (EDCs) consist of a diverse group of industrial chemicals and pharmacological agents. Evidence is accumulating that environmental chemicals (ECs) including endocrine-disrupting compounds (EDCs) can alter female repro...
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Diff...
Neoadjuvant therapy is the administration of therapeutic agents before the main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. The aim of neoadjuvant therapy is to reduce the size o...
Luteinizing hormone (LH), a gonadotropin, stimulates the gonads - in males, the testes, and in females, the ovaries. It is essential for reproduction, and secreted from cells in the anterior pituitary called gonadotrophs. In females, ovulation of mature...
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...
Cancer (malignant neoplasm) is a class of disease. There are malignancy properties that cancer cells have; 1. The diseased tissue grows uncontrollably, ignoring growth arrest signals, 2. The cells can invade and destroy adjacent tissues...
Epithelial cell adhesion molecule EpCAM CD326
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has...
UroGenRA - Genitourinary cancer array
UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently...
Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becoming malignant. About 10 per cent of bowel cancer...
